Mesoblast (MESO) Exchange Rate Effect (2016 - 2023)
Mesoblast (MESO) posted Exchange Rate Effect of $24000.0 for Q2 2023, up 142.86% sequentially from -$56000.0 in Q1 2023, and up 115.38% YoY from $11142.9 in Q2 2022.
Mesoblast (MESO) Exchange Rate Effect (2016 - 2023) Analysis & Trends
Mesoblast has reported Exchange Rate Effect for 8 years, with the latest figure at $24000.0 in Q2 2023.
- Quarterly Exchange Rate Effect rose 115.38% year-over-year to $24000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$168000.0 (up 69.45% YoY) and the FY2025 annual result came in at $1.1 million, up 2080.0% from the prior year.
- Exchange Rate Effect grew to $24000.0 in Q2 2023 per MESO's latest filing, from -$56000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $1.8 million in Q2 2020 and troughed at -$753000.0 in Q3 2022.
- A 5-year average of $122611.1 and a median of $3000.0 in 2021 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2020 and 2022: Exchange Rate Effect surged 4352.38% in 2020, then plunged 7700.0% in 2022.
- Over 5 years, Exchange Rate Effect stood at $371000.0 in 2019, then jumped by 206.2% to $1.1 million in 2020, then plunged by 93.4% to $75000.0 in 2021, then surged by 722.67% to $617000.0 in 2022, then sank by 96.11% to $24000.0 in 2023.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $24000.0, -$56000.0, and $617000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | -56,000.00 |
| Mar 31, 2023 | -56,000.00 |
| Dec 31, 2022 | 617,000.00 |
| Dec 31, 2022 | 617,000.00 |
| Sep 30, 2022 | -753,000.00 |
| Sep 30, 2022 | -753,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | -477,000.00 |
| Sep 30, 2021 | -477,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -220,000.00 |
| Mar 31, 2021 | -220,000.00 |